Peptide LibraryPetrelintide dosage in published studies and labels
These are the doses used for Petrelintide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Petrelintide has no approved dosage. Human dosing comes from Zealand Pharma's trials of once-weekly injections under the skin: in the ZUPREME 1 phase 2 trial, maintenance doses of 1.0 to 9.0 mg lowered body weight by 7.9% to 9.8% after 28 weeks against 1.7% with placebo in adults with obesity. Phase 3 trials are recruiting.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 1.0–9.0 mg once weekly in the phase 2 trial |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | 16 weeks in phase 1; 28 weeks (with follow-up to week 42) in phase 2 |
| Titration | The phase 1 multiple-dose trial escalated every 2 weeks to target doses; ZUPREME 1 reports nausea mainly during dose escalation, but its step schedule is not given in the indexed abstract. |
| Half-life | About 10 days (phase 1 trials) |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| ZUPREME 1 — phase 2, obesity (NCT06662539)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with obesity, or BMI ≥27 with hypertension or dyslipidaemia, without type 2 diabetes (485 dosed) | Maintenance doses of 1.0, 2.5, 5.0, 7.0 or 9.0 mg | Subcutaneous | Once weekly | 28 weeks (primary endpoint); follow-up to week 42 | Mean weight change from -7.9% to -9.8% across doses against -1.7% with placebo; nausea in 20% against 6% | Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026. |
| Phase 1 single and multiple ascending dosesClinical trial · Two randomized, double-blind, placebo-controlled phase 1 trials | Adults of normal weight or overweight (single dose and MAD part 1); adults with overweight or obesity (MAD part 2) | Single doses of 0.04–2.4 mg (and 0.35 mg intravenously); 0.6 or 1.2 mg weekly for 6 doses; 16 weekly doses escalated to 2.4, 4.8 or 9.0 mg | Subcutaneous | Single dose or once weekly | Up to 16 weeks | Well tolerated with no serious or severe adverse events; weight down by up to 8.6% after 16 weeks | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026. |
| Phase 3, obesity with cardiovascular disease (NCT07843472)Clinical trial · Phase 3 randomized, placebo-controlled trial | Adults with overweight or obesity and established cardiovascular disease (n=2,500 planned) | Per trial protocol (dose not given in the registry) | Subcutaneous | Per trial protocol | 64 weeks (primary endpoint) | Recruiting; no results | NCT07843472 — A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease |
Where sources disagree
- Petrelintide is an amylin analogue, like cagrilintide, but it is a different molecule with its own trial doses; cagrilintide doses do not transfer to petrelintide.
- Weight loss in ZUPREME 1 was similar from 5.0 to 9.0 mg. Phase 3 doses are not listed in the registry, and petrelintide is not FDA-approved.